A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax

被引：7
|
作者：
Wu, Jenny [1 ]
Ross, Jeremy [2 ]
Peale, Franklin V., Jr. [3 ]
Shaughnessy, John D., Jr. [4 ]
Van Laar, Ryan K. [5 ]
Morgan, Gareth J. [6 ]
Venstrom, Jeffrey M. [1 ]
Punnoose, Elizabeth A. [7 ]
机构：
[1] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Genentech Inc, Res Pathol, San Francisco, CA USA
[4] Mt Sinai Sch Med, New York, NY USA
[5] Signal Genet, Little Rock, AR USA
[6] Univ Arkansas Med Sci, Myeloma Inst, Little Rock, AR USA
[7] Genentech Inc, San Francisco, CA USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.5613.5613
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5613
引用
收藏
页数：5
相关论文
共 15 条
  • [1] BCL-2 family expression profiling may identify distinct molecular subtypes of multiple myeloma with increased susceptibility to single agent Venetoclax
    Wu, Jenny
    Stein, Caleb
    Ross, Jeremy A.
    Peale, Franklin
    Shaughnessy, John D.
    Van Laar, Ryan
    Morgan, Gareth
    Venstrom, Jeffrey M.
    Punnoose, Elizabeth A.
    Jiang, Yanwen Yanwen
    CANCER RESEARCH, 2017, 77
  • [2] Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
    Kaufman, Jonathan L.
    Gasparetto, Cristina
    Schjesvold, Fredrik H.
    Moreau, Philippe
    Touzeau, Cyrille
    Facon, Thierry
    Boise, Lawrence H.
    Jiang, Yanwen
    Yang, Xiaoqing
    Dunbar, Fengjiao
    Vishwamitra, Deeksha
    Unger, Stefanie
    Macartney, Tammy
    Pesko, John
    Yu, Yao
    Salem, Ahmed Hamed
    Ross, Jeremy A.
    Hong, Wan-Jen
    Maciag, Paulo C.
    Pauff, James M.
    Kumar, Shaji
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (04) : 418 - 427
  • [3] Deciphering a metabolic basis for single-agent venetoclax efficacy in t(11;14) multiple myeloma
    Bajpai, Richa
    Achreja, Abhinav
    Wei, Changyong
    Siddiqa, Arusha
    Matulis, Shannon M.
    Gupta, Vikas
    McBrayer, Samuel K.
    Mittal, Anjali
    Rupji, Manali
    Chen, Hsiao-Rong
    Kowalski, Jeanne
    Lonial, Sagar
    Nooka, Ajay K.
    Boise, Lawrence H.
    Nagrath, Deepak
    Shanmugam, Mala
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients
    De Ramon, Cristina
    Rojas, Elizabeta A.
    Misiewicz-Krzeminska, Irena
    Cardona-Benavides, Ignacio J.
    Cuadrado, Myriam
    Isidro, Isabel
    Calasanz, Maria-Jose
    Fernandez, Manuela
    Garcia-Sanz, Ramon
    Puig, Noemi
    Cedena, M. Teresa
    Paiva, Bruno
    Rosinol, Laura
    Martinez-Lopez, Joaquin
    Blade, Joan
    Lahuerta, Juan J.
    San Miguel, Jesus F.
    Mateos, Maria V.
    Corchete, Luis A.
    Gutierrez, Norma C.
    GEM PETHEMA Cooperat Study Grp
    HEMASPHERE, 2024, 8 (12):
  • [5] Advances in precision therapy with venetoclax in multiple myeloma with t(11;14) and high BCL2 expression: A systematic review.
    Ahmed, Zahoor
    Nabeel, Shaha
    Farooqui, Arafat Ali
    Imtiaz, Hassan
    Ashraf, Aqsa
    Farooq, Umer
    Din, Mohammad Ammad Ud
    Wahab, Ahsan
    Rehman, Saif ur
    Anwer, Faiz
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
    Punnoose, Elizabeth A.
    Leverson, Joel D.
    Peale, Franklin
    Boghaert, Erwin R.
    Belmont, Lisa D.
    Tan, Nguyen
    Young, Amy
    Mitten, Michael
    Ingalla, Ellen
    Darbonne, Walter C.
    Oleksijew, Anatol
    Tapang, Paul
    Yue, Peng
    Oeh, Jason
    Lee, Leslie
    Maiga, Sophie
    Fairbrother, Wayne J.
    Amiot, Martine
    Souers, Andrew J.
    Sampath, Deepak
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) : 1132 - 1144
  • [7] Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
    Sharon, David
    Dunbar, Fengjiao
    Jung, Paul
    Wang, Xifeng
    Li, Xiaotong
    Mantis, Christine
    Bueno, Orlando F.
    Touzeau, Cyrille
    Moreau, Philippe
    Harrison, Simon J.
    Costa, Luciano J.
    Kaufman, Jonathan L.
    Bahlis, Nizar J.
    Kumar, Shaji K.
    Ross, Jeremy A.
    Epling-Burnette, P. K.
    BLOOD, 2022, 140 : 4242 - 4244
  • [8] Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience
    Ionescu, Filip
    Patel, Parth
    Thapa, Shrinjaya
    Drekolias, Dimitrios
    Blue, Brandon Jamaal
    Puglianini, Omar Alexis Castaneda
    Ochoa-Bayona, Jose L.
    Freeman, Ciara L.
    Liu, Hien
    Hansen, Doris K.
    Nishihori, Taiga
    Silva, Ariosto
    Sudalagunta, Praneeth Reddy
    Brayer, Jason B.
    Alsina, Melissa
    Shain, Kenneth H.
    Baz, Rachid C.
    Grajales-Cruz, Ariel Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
    Touzeau, C.
    Dousset, C.
    Le Gouill, S.
    Sampath, D.
    Leverson, J. D.
    Souers, A. J.
    Maiga, S.
    Bene, M. C.
    Moreau, P.
    Pellat-Deceunynck, C.
    Amiot, M.
    LEUKEMIA, 2014, 28 (01) : 210 - 212
  • [10] The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
    C Touzeau
    C Dousset
    S Le Gouill
    D Sampath
    J D Leverson
    A J Souers
    S Maïga
    M C Béné
    P Moreau
    C Pellat-Deceunynck
    M Amiot
    Leukemia, 2014, 28 : 210 - 212
12